PRINCETON, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the ...
On Thursday, Anthropic announced Claude 3.5 Sonnet, its latest AI language model and the first in a new series of “3.5” models that build upon Claude 3, launched in March. Claude 3.5 can compose text, ...
Sonnet Labs has introduced a new device that enables smartphones to connect with each other without the need for network connectivity. Yes, the Sonnet lets you survive off the grids without having to ...
Sonnet BioTherapeutics Holdings, Inc. recently participated in the Virtual Investor "Top 5 for ‘25” On-Demand Conference, where CEO Pankaj Mohan, Ph.D., outlined five reasons for the investment ...
The AI arms race shows no signs of slowing down this year, with Anthropic the latest major player to refresh its offering with the launch of Claude 3. In short, Claude 3 is AI unicorn Anthropic’s new ...
Now’s the time for “American Sonnets for My Past and Future Assassin,” Terrance Hayes’ electric, new book. In his five previous poetry collections — “Muscular Music” (1999), “Hip Logic” (2002), “Wind ...
Sonnet is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB (Fully Human Albumin-Binding), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback